The decision making process in AML integrates clinical features, an increasing amount of genetic information and minimal residual disease (MRD) data. Combining these data aims at answering the following questions:

  • do I treat my patient with an intensive (= curative) or a non intensive (= non-curative) approach ?
  • do I have therapeutic targets to improve the current treatment?
  • is there an indication for a stem cell transplantation (SCT), maintenance therapy, etc.

Each new edition of ASH brings some new answers. This was again the case at the 2016 annual ASH meeting.

(BELG J HEMATOL 2017;8(1):29–33)